Clinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11-year epidemiologic survey.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 30 03 2021
accepted: 18 10 2021
pubmed: 7 11 2021
medline: 1 2 2022
entrez: 6 11 2021
Statut: ppublish

Résumé

Polymicrobial bloodstream infections (pBSI) occurring in hematological patients are still poorly understood, and specific information are very limited. In this epidemiologic survey, we describe clinical characteristics and outcome of 125 consecutive pBSI occurred in oncohematological patients. Polymicrobial bloodstream infections (pBSI) were defined with the isolation of 2 or more bacteria from blood culture specimens obtained within 72 h. Over an 11-year period, we documented 500 bacterial bloodstream infections (BSI) in 4542 hospital admissions and 25% (125) of these were pBSI. Most common underlying hematological disease was acute myeloid leukemia and 89% of patients had severe neutropenia. Fifty pBSI (40%) occurred in patients undergoing a stem cell transplantation (SCT), mostly within 30 days from transplant (42/50-84%). Principal bacterial association was Gram-positive plus Gram-negative (57%). Resolution rate of pBSI was 82%, without differences between SCT and non-SCT cases. pBSI-related mortality was 15% (6% in SCT cases). Septic shock occurred in 16% of cases and septic shock-related mortality was 65% (75% in SCT cases and 63% in non-SCT cases; p = 0.6). Multidrug-resistant (MDR) bacteria were involved in 22% of pBSI and the MDR-pBSI-related mortality was significantly higher in SCT patients (p = 0.007). This observational study highlights that pBSI is not a rare bloodstream infectious complication in oncohematological patients. pBSI-related mortality is lower than 20%, but, if septic shock occurs, mortality reaches 65%. MDR bacteria were involved in 22% of cases and pBSI-MDR-related mortality was significantly higher in SCT patients.

Sections du résumé

BACKGROUND BACKGROUND
Polymicrobial bloodstream infections (pBSI) occurring in hematological patients are still poorly understood, and specific information are very limited.
OBJECTIVES AND METHODS OBJECTIVE
In this epidemiologic survey, we describe clinical characteristics and outcome of 125 consecutive pBSI occurred in oncohematological patients. Polymicrobial bloodstream infections (pBSI) were defined with the isolation of 2 or more bacteria from blood culture specimens obtained within 72 h.
RESULTS RESULTS
Over an 11-year period, we documented 500 bacterial bloodstream infections (BSI) in 4542 hospital admissions and 25% (125) of these were pBSI. Most common underlying hematological disease was acute myeloid leukemia and 89% of patients had severe neutropenia. Fifty pBSI (40%) occurred in patients undergoing a stem cell transplantation (SCT), mostly within 30 days from transplant (42/50-84%). Principal bacterial association was Gram-positive plus Gram-negative (57%). Resolution rate of pBSI was 82%, without differences between SCT and non-SCT cases. pBSI-related mortality was 15% (6% in SCT cases). Septic shock occurred in 16% of cases and septic shock-related mortality was 65% (75% in SCT cases and 63% in non-SCT cases; p = 0.6). Multidrug-resistant (MDR) bacteria were involved in 22% of pBSI and the MDR-pBSI-related mortality was significantly higher in SCT patients (p = 0.007).
CONCLUSIONS CONCLUSIONS
This observational study highlights that pBSI is not a rare bloodstream infectious complication in oncohematological patients. pBSI-related mortality is lower than 20%, but, if septic shock occurs, mortality reaches 65%. MDR bacteria were involved in 22% of cases and pBSI-MDR-related mortality was significantly higher in SCT patients.

Identifiants

pubmed: 34741656
doi: 10.1007/s00520-021-06640-9
pii: 10.1007/s00520-021-06640-9
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2359-2366

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36(9):1103–1110
doi: 10.1086/374339
Tumbarello M, Trecarichi EM, Caira M et al (2012) Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. PLoS ONE 7(12):8–11
doi: 10.1371/journal.pone.0051612
Pagano L, Caira M, Rossi G et al (2012) A prospective survey of febrile events in hematological malignancies. Ann Hematol 91(5):767–774
doi: 10.1007/s00277-011-1373-2
Kolonen A, Sinisalo M, Huttunen R et al (2017) Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol–a prospective nationwide study. Infect Dis (Auckl) 49(11–12):799–808
doi: 10.1080/23744235.2017.1347814
Elting LS, Rubenstein EB, Rolston KVI, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259
doi: 10.1086/514550
Mikulska M, Del Bono V, Bruzzi P et al (2012) Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 40(3):271–278
doi: 10.1007/s15010-011-0229-y
Nørgaard M, Larsson H, Pedersen G, Schønheyder HC, Sørensen HT (2006) Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect 12(3):217–223
doi: 10.1111/j.1469-0691.2005.01298.x
Samonis G, Vardakas KZ, Maraki S et al (2013) A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 21(9):2521–2526
doi: 10.1007/s00520-013-1816-5
Valentine JC, Hall L, Spelman T, et al. Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. Support Care Cancer. 2020;
Royo-Cebrecos C, Gudiol C, Ardanuy C, Pomares H, Calvo M, Carratalà J (2017) A fresh look at polymicrobial bloodstream infection in cancer patients. PLoS ONE 12(10):1–12
doi: 10.1371/journal.pone.0185768
Rolston KVI, Bodey GP, Safdar A (2007) Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 45(2):228–233
doi: 10.1086/518873
Pavlaki M, Poulakou G, Drimousis P et al (2013) Polymicrobial bloodstream infections: Epidemiology and impact on mortality. J Glob Antimicrob Resist 1(4):207–212
doi: 10.1016/j.jgar.2013.06.005
Trecarichi EM, Tumbarello M, Spanu T et al (2009) Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58(4):299–307
doi: 10.1016/j.jinf.2009.02.002
Trecarichi EM, Tumbarello M (2014) Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis 27(2):200–210
doi: 10.1097/QCO.0000000000000038
Gudiol C, Bodro M, Simonetti A et al (2013) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 19(5):474–479
doi: 10.1111/j.1469-0691.2012.03879.x
Cattaneo C, Casari S, Bracchi F et al (2010) Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis. 42(5):324–32
doi: 10.3109/00365540903496569
Tomlinson D, Mermel LA, Ethier MC et al (2011) Defining bloodstream infections related to central venous catheters in patients with cancer: a systematic review. Clin Infect Dis 53(7):697–710
doi: 10.1093/cid/cir523
Singer M, Deutschman CS, Seymour C et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA J Am Med Assoc 315(8):801–810
doi: 10.1001/jama.2016.0287
Averbuch D, Orasch C, Cordonnier C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98(12):1826–35
doi: 10.3324/haematol.2013.091025
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4).
Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792
doi: 10.1007/s00277-017-3098-3
Penack O, Becker C, Buchheidt D et al (2014) Management of sepsis in neutropenic patients: 2014 Updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol 93(7):1083–1095
doi: 10.1007/s00277-014-2086-0
Lin JN, Lai CH, Chen YH et al (2010) Characteristics and outcomes of polymicrobial bloodstream infections in the emergency department: a matched case-control study. Acad Emerg Med 17(10):1072–1079
doi: 10.1111/j.1553-2712.2010.00871.x
Sancho S, Artero A, Zaragoza R, Camarena JJ, González R, Nogueira JM (2012) Impact of nosocomial polymicrobial bloodstream infections on the outcome in critically ill patients. Eur J Clin Microbiol Infect Dis 31(8):1791–1796
doi: 10.1007/s10096-011-1503-8
Shareaier C, Linke L, Eder M et al (2020) Incidence, risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients. PLoS One 15(1):e0227772
doi: 10.1371/journal.pone.0227772

Auteurs

Gabriele Facchin (G)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy. gabriele.facchin.92@gmail.com.

Anna Candoni (A)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.

Davide Lazzarotto (D)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.

Maria Elena Zannier (ME)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.

Maddalena Peghin (M)

Division of Infectious Diseases, University Hospital ASUFC, Udine, Italy.

Emanuela Sozio (E)

Division of Infectious Diseases, University Hospital ASUFC, Udine, Italy.

Nicolò Pellegrini (N)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.

Carla Filì (C)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.

Assunta Sartor (A)

Clinical Microbiology, University Hospital ASUFC, Udine, Italy.

Carlo Tascini (C)

Division of Infectious Diseases, University Hospital ASUFC, Udine, Italy.

Renato Fanin (R)

Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH